Sawai Group Holdings Co., Ltd. (TYO:4887)

Market Cap	206.60B -8.7%
Revenue (ttm)	201.68B +6.7%
Net Income	10.44B -12.8%
EPS	81.52 -15.3%
Shares Out	115.49M
PE Ratio	19.86
Forward PE	10.84
Dividend	55.00 (3.09%)
Ex-Dividend Date	Mar 30, 2026

Volume	579,000
Average Volume	481,870
Open	1,815.00
Previous Close	1,805.00
Day's Range	1,778.50 - 1,823.00
52-Week Range	1,730.50 - 2,447.00
Beta	n/a
RSI	27.09
Earnings Date	May 15, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 3,310
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4887

Financial Performance

In fiscal year 2026, Sawai Group Holdings's revenue was 201.68 billion, an increase of 6.69% compared to the previous year's 189.02 billion. Earnings were 10.44 billion, a decrease of -12.79%.